June 2025 - Page 9 of 14

Release – Aurania Reports on ARCOM Announcement in Ecuador

Posted on June 11, 2025June 11, 2025 by aweinsoff@channelchek.com

June 11, 2025 7:12 AM EDT | Source: Aurania Resources Ltd.

Toronto, Ontario–(Newsfile Corp. – June 11, 2025) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) reports on a resolution recently put forth by the Ecuadorian Control and Regulation Agency (“ARCOM” for its Spanish acronym) related to a new administrative fee on the mining sector. This resolution has not yet been published in the Official Registry, and therefore, to our knowledge is not yet in effect.

The intention of this resolution is for all participants in the mining/exploration industry in Ecuador to fund ARCOM’s efforts to stop illegal mining, strengthen oversight, and enhance the operational capacity of ARCOM.

The document provides assessments of the amount each mining/exploration company is expected to pay based on the type of regime, size of concessions and stage of exploration. As presented, this proposed fee would require the Company to pay approximately US$24 million this year by July 31st. This figure is insupportable and represents approximately ten times the amount the Company pays for its annual concession fees in Ecuador.

The Company is collaborating with the Mining Chamber of Ecuador’s legal commission and all other mining/exploration companies in Ecuador, to ensure that relevant authorities understand that this fee is not feasible and will likely place the whole mining/exploration industry in Ecuador at risk. If the resolution is implemented as currently outlined, the regulation would result in an unsustainable cost burden for companies operating within the sector and may undermine confidence in Ecuador’s regulatory consistency and commitment to mining development.

The Company has reached out to the Ecuadorian Government at the highest levels and will continue in discussions with the Mining Chamber of Ecuador and the Company’s respective legal counsels as joint industry efforts are taking place to prevent this regulation from being implemented. The Company will assess options for further courses of action.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
VP Corporate Development & Investor Relations
Aurania Resources Ltd.
(416) 367-3200
carolyn.muir@aurania.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release contains forward-looking information as such term is defined in applicable securities laws, which relate to future events or future performance and reflect management’s current expectations and assumptions. The forward-looking information includes statements regarding the ARCOM resolution, its impact on the Company and the mining sector in Ecuador, and Aurania’s objectives, goals and future plans in light of the ARCOM resolution. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to Aurania, including the current status of the ARCOM resolution and the interpretation of the application of the resolution. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Risk factors that could cause actual results to differ materially from the results expressed or implied by the forward-looking information include, among other things, the failure of efforts to dissuade the relevant authorities to proceed with the ARMCOM resolution, the publication of the ARCOM resolution in its current form, an application of the ARCOM resolution of more severe consequences than currently understood and a lack of options for further courses of action, including legal action which would not provide appropriate relief and, generally, the additional risks identified in our filings with Canadian securities regulators on SEDAR+ (available at www.sedarplus.ca). Aurania cautions the reader that the above list of risk factors is not exhaustive. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described, or intended. Investors are cautioned against undue reliance on forward-looking statements or information. These forward-looking statements are made as of the date hereof and, except as required by applicable securities regulations, the Company does not intend, and does not assume any obligation, to update the forward-looking information.

SOURCE: Aurania Resources Ltd.

Xcel Brands (XELB) – Positioned For A Much Bigger Company

Posted on June 11, 2025June 11, 2025 by slightbourne@noblecapitalmarkets.com

Wednesday, June 11, 2025

Xcel Brands, Inc. 1333 Broadway 10th Floor New York, NY 10018 United States https:/Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 84 Key Executives Name Title Pay Exercised Year Born Mr. Robert W. D’Loren Chairman, Pres & CEO 1.27M N/A 1958 Mr. James F. Haran CFO, Principal Financial & Accou

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 results. First quarter results indicated a modest improvement from Q4, but it was a slow start to the year. First quarter revenues were $1.3 million, and the company reported an adj. EBITDA loss of $0.7 million from continuing operations. We believe the company is well positioned to benefit from a number of favorable developments, including the launch of new brands, contributions from Halston, and a lower cost base.

Strategic partnerships. Notably, the company announced a series of new strategic partnerships this year with Jenny Martinez, Gemma Stafford, and Cesar Millan. These new strategic partnerships expand the company’s product offerings into pet products, bakeware, kitchenware, and home essentials. Furthermore, the new celebrity partnerships bring a large number of social media followers, which supports the company’s effort to reach 100 million social media followers in 2026.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Unicycive Therapeutics (UNCY) – FDA Finds Deficiencies At Third-Party Manufacturing Subcontractor – Approval Could Be Delayed

Posted on June 11, 2025June 11, 2025 by slightbourne@noblecapitalmarkets.com

Wednesday, June 11, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Approval May Come After The PDUFA Date Of June 28. Unicycive announced that an FDA inspection has found deficiencies with the cGMP (certified Good Manufacturing Practice) compliance at a third-party manufacturing subcontractor. The company’s product, OLC, is manufactured by a contract manufacturer with other subcontractors. The deficiency does not involve the active pharmaceutical compound (APC) and may be related to final finishing and packaging operations.

Good News and Bad News. The FDA stated that the manufacturing deficiencies must be resolved before product label discussions can proceed. We interpret this to mean that the FDA review of the clinical data has been completed, the manufacturing inspection was conducted, and product labeling remains as the final step before approval. Although the manufacturing deficiencies have stopped the labeling discussion, we expect NDA approval when corrected.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

The GEO Group (GEO) – Some More Good News

Posted on June 11, 2025June 11, 2025 by slightbourne@noblecapitalmarkets.com

Wednesday, June 11, 2025

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Favorable Adelanto Outcome. The GEO Group received some more good news yesterday with the U.S. District Court, Central District of California, approving a settlement that allows for immediate full intake at GEO’s 1,940-bed Adelanto ICE Processing Center in California. Recall, previous court rulings had limited the use of Adelanto based on the then prevailing COVID-19 conditions.

Another Uplift. Under a January 20025 ruling, the Court had allowed the facility to increase its population cap to 475 detainees. At full occupancy and under the current contract, GEO would see an uplift in revenue of some $31 million, with margins consistent with other Company-owned Secure Service facilities. Adding in Monday’s D. Ray James announcement, GEO could be looking at $100 million of additional revenue and approximately $26 million of net operating income on an annual basis.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

MustGrow Biologics Corp. (MGROF) – Another Arrow in the Quiver

Posted on June 11, 2025June 11, 2025 by slightbourne@noblecapitalmarkets.com

Wednesday, June 11, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another Arrow. Yesterday, MustGrow added another arrow to its NexusBioAg product quiver with the signing of a distribution agreement with Phospholutions Inc., whereby MustGrow will sell Phospholutions’ RhizoSorb product in Canada. The new agreement further broadens NexusBioAg’s product offerings in Canada.

RhizoSorb. Phospholutions’ mission is to enhance global phosphorus use, a critical fertilizer for food production. Phosphorus is the second most used nutrient in global food production. RhizoSorb was developed to cut costs and reduce the environmental impact of fertilizer use by releasing nutrients in the soil more efficiently. The product has been through over 500 trials, including over 400 field trials. Notably, Phospholutions has signed a distribution agreement with The Andersons (NASDAQ:ANDE) for RhizoSorb distribution in the U.S.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Century Lithium Corp. (CYDVF) – Century Lithium Commences LIFE Offering Financing

Posted on June 11, 2025June 11, 2025 by slightbourne@noblecapitalmarkets.com

Wednesday, June 11, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

LIFE offering. Century Lithium has commenced an offering, under the Listed Issuer Financing Exemption (LIFE), to raise a minimum of C$2,000,000 and a maximum of C$5,000,000 with an offering of up to 16,666,667 units at a price of C$0.30 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at an exercise price of C$0.45 for a period of 24 months following the issuance of the units. After selling commissions, fees, and estimated offering costs, the company expects to receive net proceeds of C$1,810,000 to C$4,600,000.

Use of net proceeds. Net proceeds from the financing will be used to complete an updated feasibility study for the company’s Angel Island Lithium Project, complete the project’s Plan of Operations, work towards National Environmental Policy Act (NEPA) compliance, and general working capital. The offering is expected to close on or about July 7 and is not expected to close in tranches.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Inflation Data and Treasury Auctions Put Bond Market on High Alert This Week

Posted on June 11, 2025June 11, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– CPI and PPI inflation reports for May are due this week, with modest increases expected but upside risks from tariffs.
– Treasury auctions of 10- and 30-year bonds will test investor demand amid rising deficits and higher yields.
– The results may influence Federal Reserve policy and market volatility, especially if inflation surprises to the upside.

Investors are bracing for a potentially volatile week as key inflation reports and large government bond auctions test the strength of the U.S. fixed income market. With concerns rising around growing fiscal deficits, tariffs, and monetary policy uncertainty, both data and demand will be under a microscope.

The Bureau of Labor Statistics is set to release two important indicators: the Consumer Price Index (CPI) for May on Wednesday, followed by the Producer Price Index (PPI) on Thursday. These readings come at a delicate time for markets already on edge over the potential long-term impact of President Trump’s recent tariffs and record government spending.

Economists forecast modest increases, with CPI expected to rise 0.2% month-over-month and 2.4% year-over-year. The core CPI, which excludes food and energy, is projected to climb 0.3% from April and 2.9% annually. Producer prices, which declined in April, are expected to bounce back slightly, with consensus pointing to a 0.2% monthly gain in headline PPI and 0.3% in the core reading.

However, any upward surprise in the data could disrupt fragile investor sentiment, especially as rising inflationary pressures threaten to delay future interest rate cuts by the Federal Reserve. Traders will be closely analyzing the data for signs of whether the recent tariffs are starting to flow through to consumer and producer prices.

Compounding the pressure, the U.S. Treasury will hold two major auctions this week: $39 billion in 10-year notes on Wednesday and $22 billion in 30-year bonds on Thursday. These long-duration securities will act as a litmus test for investor demand at a time when U.S. debt levels are drawing increased scrutiny from both markets and policymakers.

Key metrics from the auctions — such as the bid-to-cover ratio, the level of indirect bids, and the yield “tail” — will offer insight into how much appetite exists for U.S. debt amid rising deficits. Yields have already surged in recent weeks as investors demand greater compensation for holding Treasurys amid growing fiscal and geopolitical risks.

While the market remains relatively stable for now, analysts warn that a sudden jump in yields — driven either by weak auction demand or unexpected inflationary pressure — could send ripple effects across equities, credit markets, and consumer borrowing costs.

The bond market has been adjusting ever since the Fed’s rate cut last September, with yields taking another leg higher following Trump’s early April tariff announcement. The impact of these policies may be further amplified if inflation data begins trending upward over the coming months.

Even amid concerns, some analysts remain cautiously optimistic. Strong relative yields on U.S. Treasurys compared to global peers and signs of a cooling economy may continue to attract foreign and institutional investors seeking safety and steady returns.

Still, with inflation readings, bond supply, and fiscal policy all converging this week, investors are likely to remain on high alert. The outcomes of these events could shape not only the direction of yields but also the Federal Reserve’s monetary roadmap heading into the second half of 2025.

Release – ACCO Brands Announces Leadership Changes

Posted on June 10, 2025June 11, 2025 by aweinsoff@channelchek.com

News Research and Market Data on ACCO

June 10, 2025

LAKE ZURICH, Ill.–(BUSINESS WIRE)–ACCO Brands Corporation (NYSE: ACCO) — the leader in branded consumer and office products — announced changes to its senior executive leadership team, in connection with the multi-year restructuring and cost savings program initiated last year. These important moves are a continuation of the company’s efforts to simplify the operating structure and bring key leaders closer to the customer, and to better leverage our global sourcing capabilities.

Effective August 1, 2025, Patrick Buchenroth, Executive Vice President of ACCO Brands and President of the Americas segment will be leaving the company. The company will continue reporting two segments, the Americas segment and the International segment. Effective July 1, 2025, the Americas operating segment will be led by John “Jed” Peters, newly named Senior Vice President, ACCO Brands and President, North America, who will be leading the company’s commercial businesses in the U.S. and Canada, and Rubens Passos, Senior Vice President, who will be leading its businesses in Brazil, Mexico, Chile and export markets in Latin America.

Effective December 31, 2025, Cezary Monko, Executive Vice President of ACCO Brands and President of the International segment will begin his transition out of the company. Ard-Jen “AJ” Spijkervet has been appointed Senior Vice President, ACCO Brands and President, International effective January 1, 2026. Spijkervet will be responsible for all commercial activities in EMEA, Australia, New Zealand, Asia and the export markets in the Middle East and Africa.

“We are focused on delivering sustained, profitable sales growth, and our leadership team is committed to providing value to our customers and consumers. As we continue to optimize our cost structure and deliver best in class service, we are well positioned for the future. In addition, I would like to thank Pat and Cezary for their significant contributions to ACCO Brands and their leadership of our business,” said Tom Tedford, President and Chief Executive Officer of ACCO Brands.

Executive Biographies

Jed Peters

Jed Peters brings 27 years expertise in the office products industry and at ACCO Brands, starting as a management trainee at the company in 1998. During that time, Peters has developed deep relationships with our North American customer and consumer base through roles of increasing responsibilities within the marketing, sales and global product development functions. Most recently, he served as General Manager, U.S. School & Office Products and PowerA. Peters has an MBA from the Kellogg School of Management at Northwestern University and a Marketing degree from Notre Dame.

AJ Spijkervet

AJ Spijkervet has more than 30 years of international business experience. He joined ACCO Brands in 2016 as part of the Esselte acquisition where he held several key roles over his tenure, including Vice President of Marketing EMEA, Marketing & Sales in China, as well as Marketing Director for Central Europe. Spijkervet is currently serving as Vice President for Central Europe. Prior to Esselte/ACCO Brands, he worked in the consumer goods industry spanning International Sales & Marketing, Trade-& Brand-Marketing and Operations. Spijkervet earned a master’s degree in International Marketing & Strategy from the University of Groningen, Netherlands and a bachelor’s degree in Industrial Engineering from NHL Stenden University.

Rubens Passos

Rubens Passos has 40 years of international business experience, joining ACCO Brands in 2012 as part of the Mead Consumer and Office Products acquisition where he held key positions including CFO and President of the business in Brazil. He has served as SVP Latin America and is currently serving as SVP Latin America and interim General Manager for the business in Canada. Prior to Mead/ACCO Brands, he held key leadership positions working in Consumer Goods, Pulp & Paper and Telecom. Passos holds an MBA from the Fuqua School of Business at Duke University and an undergraduate degree in Economics from F.A.A.P. in Sao Paulo Brazil.

About ACCO Brands Corporation

ACCO Brands is the leader in branded consumer products that enable productivity, confidence and enjoyment while working, when learning and while playing. Our widely recognized brands include AT-A-GLANCE^®, Five Star^®, Kensington^®, Leitz^®, Mead^®, PowerA^®, Swingline^®, Tilibra^® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

Forward-Looking Statements

Statements contained herein, other than statements of historical fact, particularly those anticipating future financial performance, business prospects, growth, strategies, business operations and similar matters, results of operations, liquidity and financial condition, and those relating to cost reductions and anticipated pre-tax savings and restructuring costs are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “forecast,” “project,” “plan,” and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them. Forward-looking statements are subject to the occurrence of events outside the Company’s control and actual results and the timing of events may differ materially from those suggested or implied by such forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements when deciding whether to buy, sell or hold the Company’s securities.

Among the factors that could cause our actual results to differ materially from our forward-looking statements are: changes in trade policy and regulations, including changes in trade agreements and the imposition of tariffs, and the resulting consequences; global political and economic uncertainties; a limited number of large customers account for a significant percentage of our sales; sales of our products are affected by general economic and business conditions globally and in the countries in which we operate; risks associated with foreign currency exchange rate fluctuations; challenges related to the highly competitive business environment in which we operate; our ability to develop and market innovative products that meet consumer demands and to expand into new and adjacent product categories; our ability to successfully expand our business in emerging markets and the exposure to greater financial, operational, regulatory, compliance and other risks in such markets; the continued decline in the use of certain of our products; risks associated with seasonality, the sufficiency of investment returns on pension assets, risks related to actuarial assumptions, changes in government regulations and changes in the unfunded liabilities of a multi-employer pension plan; any impairment of our intangible assets; our ability to secure, protect and maintain our intellectual property rights, and our ability to license rights from major gaming console makers and video game publishers to support our gaming accessories business; our ability to grow profitably through acquisitions, and successfully integrate them; our ability to successfully execute our multi-year restructuring and cost savings program and realize the anticipated benefits; continued disruptions in the global supply chain; risks associated with inflation and other changes in the cost or availability of raw materials, transportation, labor, and other necessary supplies and services and the cost of finished goods; risks associated with outsourcing production of certain of our products, information technology systems and other administrative functions; the failure, inadequacy or interruption of our information technology systems or its supporting infrastructure; risks associated with a cybersecurity incident or information security breach, including that related to a disclosure of personally identifiable information; risks associated with our indebtedness, including limitations imposed by restrictive covenants, our debt service obligations, and our ability to comply with financial ratios and tests; a change in or discontinuance of our stock repurchase program or the payment of dividends; product liability claims, recalls or regulatory actions; the impact of litigation or other legal proceedings; the impact of additional tax liabilities stemming from our global operations and changes in tax laws, regulations and tax rates; our failure to comply with applicable laws, rules and regulations and self-regulatory requirements, the costs of compliance and the impact of changes in such laws; our ability to attract and retain qualified personnel; the volatility of our stock price; risks associated with circumstances outside our control, including those caused by telecommunication failures, labor strikes, power and/or water shortages, public health crises, such as the occurrence of contagious diseases, severe weather events, war, terrorism and other geopolitical incidents; and other risks and uncertainties described in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and in other reports we file with the Securities and Exchange Commission.

Contacts

For further information:

Christopher McGinnis
Investor Relations
(847) 796-4320

Kori Reed
Media Relations
(224) 501-0406

Release – CoreCivic Enters Into Definitive Agreement to Acquire The Farmville Detention Center

Posted on June 10, 2025June 11, 2025 by aweinsoff@channelchek.com

Research New and Market Data on CXW

June 10, 2025

PDF Version

BRENTWOOD, Tenn., June 10, 2025 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it has entered into a definitive agreement to acquire the Farmville Detention Center, a 736-bed facility constructed in 2010 and located in Farmville, Virginia. The transaction is expected to be consummated through the acquisition of 100% of the membership interests in entities that own the facility. Farmville Detention Center provides transportation, care, and civil detention services to adult male noncitizens through an Intergovernmental Service Agreement between Prince Edward County, Virginia and U.S. Immigration & Customs Enforcement (“ICE”), which expires in March 2029.

The total purchase price, amounting to $67.0 million, is expected to be funded with cash on hand and borrowing capacity under CoreCivic’s revolving bank credit facility. The acquisition, which is subject to the satisfaction of customary closing conditions, is expected to close effective July 1, 2025, and result in total annual incremental revenue of approximately $40.0 million.

Damon T. Hininger, CoreCivic’s Chief Executive Officer, commented, “We are pleased to expand our immigration solutions with this critical location, which ICE has used for many years — a need we expect to continue for the foreseeable future.” Patrick D. Swindle, CoreCivic’s President and Chief Operating Officer, added “We look forward to assuming the operation at this location, and welcoming more than 200 new employees to the CoreCivic team.”

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes statements as to our beliefs and expectations of the outcome of future events that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements may include such words as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Such forward-looking statements may be affected by risks and uncertainties in CoreCivic’s business and market conditions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. Important factors that could cause actual results to differ are described in the filings made from time to time by CoreCivic with the Securities and Exchange Commission (“SEC”) and include the risk factors described in CoreCivic’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 21, 2025. Except as required by applicable law, CoreCivic undertakes no obligation to update forward-looking statements made by it to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events.

Contact:	Investors: David Garfinkle – Chief Financial Officer – (615) 263-3008
	Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

Posted on June 10, 2025June 10, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GOVX

ATLANTA, GA, June 10, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today announced that clinical data for its next-generation COVID-19 multi-antigen vaccine candidate, GEO-CM04S1, will be presented at the European Hematology Association (EHA) 2025 Hybrid Congress, taking place June 12–15, 2025, in Milan, Italy and online.

Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center in Duarte, California, will present a poster titled: “MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study”. The poster will be featured on Saturday, June 14, 2025, from 18:30 to 18:30 CEST in the Poster Hall, as part of the session on Infections in Hematology (including supportive care/therapy).

The presentation will highlight initial results from a Phase II randomized clinical trial highlighting the superior cellular immune response of GEO-CM04S1 compared to an authorized mRNA-based COVID-19 vaccine in CLL patients—a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction. The findings will underscore the differentiated mechanism and clinical potential of the GeoVax MVA multi-antigen platform, particularly in immunocompromised individuals.

“GEO-CM04S1 continues to show promise as a vaccine option for populations with suboptimal protection from existing COVID-19 vaccines,” said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. “We are proud to have these important data showcased at EHA2025, reflecting the real-world needs of patients with hematologic malignancies.”

About GEO-CM04S1

GEO-CM04S1 is a multi-antigen COVID-19 vaccine designed using a synthetic Modified Vaccinia Ankara (MVA) vector platform. The vaccine expresses both spike (S) and nucleocapsid (N) antigens of SARS-CoV-2, aiming to provide broader and more durable immune protection. It is currently being evaluated in Phase 2 clinical trials in both immunocompromised and healthy adults.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Company Contact:

info@geovax.com

678-384-7220

Investor Relations Contact:

geovax@precisionaq.com

212-698-8696

Release – Vince Announces Reporting Date for First Quarter 2025 Financial Results

Posted on June 10, 2025June 10, 2025 by aweinsoff@channelchek.com

Research News and Market Data on VNCE

NEW YORK–(BUSINESS WIRE)–Vince Holding Corp., (NYSE: VNCE) (“VNCE” or the “Company”), a global contemporary retailer, today announced that it plans to report its first quarter 2025 financial results pre-market on Tuesday, June 17, 2025. The Company also plans to hold a conference call to discuss its financial results on the same day at 8:30 a.m. ET. During the conference call, the Company may answer questions concerning business and financial developments, trends and other business or financial matters. The Company’s responses to these questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been previously disclosed.

Those who wish to participate in the call may do so by dialing 833-470-1428, conference ID 598215. Any interested party will also have the opportunity to access the call via the Internet at http://investors.vince.com/. To listen to the live call, please go to the website at least 15 minutes early to register and download any necessary audio software. For those who cannot listen to the live broadcast, a recording will be available for 12 months after the date of the event. Recordings may be accessed at http://investors.vince.com/.

ABOUT VINCE HOLDING CORP.

Vince Holding Corp. is a global retail company that operates the Vince brand women’s and men’s ready to wear business. Vince, established in 2002, is a leading global luxury apparel and accessories brand best known for creating elevated yet understated pieces for every day effortless style. Vince Holding Corp. operates 44 full-price retail stores, 14 outlet stores, and its e-commerce site, vince.com, as well as through premium wholesale channels globally. Please visit www.vince.com for more information.

This press release is also available on the Vince Holding Corp. website (http://investors.vince.com/).

Contacts

Investor Relations:
ICR, Inc.
Caitlin Churchill, 646-277-1274
Caitlin.Churchill@icrinc.com

Release – Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Posted on June 10, 2025June 10, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GYRE

June 10, 2025

PDF Version

SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (“ETA”) receptor antagonist, for the treatment of pulmonary arterial hypertension (“PAH”).

This milestone marks Gyre’s entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China’s National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China’s PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.

F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH progression.

The Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre’s fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.

F230 joins Gyre’s pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application (“NDA”) submission to China’s National Medical Products Administration (“NMPA”) is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis (“MASH”) fibrosis.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and F230.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre’s research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
David Zhang
Gyre Therapeutics
david.zhang@gyretx.com

Release – MustGrow and Phospholutions Sign Canadian Distribution Agreement for Phosphorous Efficiency Product – RhizoSorb®

Posted on June 10, 2025June 10, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MGROF

Distribution agreement in Canada under MustGrow’s sales and distribution division NexusBioAg.
RhizoSorb^® releases nutrients in the soil more efficiently to reduce phosphorus use by up to 50% while maximizing crop yield.
Sustainable production and responsible use of phosphorus is critical to support global food demands.

SASKATOON, Saskatchewan, Canada, June 10, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”), a leading provider of biological and regenerative agriculture solutions, is pleased to announce the addition of Phospholutions Inc.’s (“Phospholutions”) RhizoSorb^® phosphorous efficiency product. MustGrow and Phospholutions have signed a distribution agreement whereby MustGrow will sell RhizoSorb^®through its Canadian sales and distribution division, NexusBioAg (website: NexusBioAg).

Traditionally, the majority of applied phosphates are quickly tied up in soil, making them unavailable for plant uptake. As little as 10% of conventional phosphorus fertilizer is used by the crop. RhizoSorb^® offers a controlled release, avoiding tie up while decreasing nutrient leaching.

RhizoSorb^® Product Highlights¹

RhizoSorb^® patented technology is designed to replace conventional commodity fertilizers like monoammonium phosphate (“MAP”) and diammonium phosphate (“DAP”), by enhancing nutrient use efficiency through its integration into dry-granule phosphate production. It offers the same ease of application as traditional granular fertilizers, requiring no changes to existing equipment or practices.

RhizoSorb^® increases phosphorus efficiency by up to 50%, allowing farmers to apply half the applied phosphorus of their traditional fertilizer while maintaining, and even improving yield. This efficiency translates to better grower return on investment, with potential savings of up to US$20 per acre by optimizing fertilizer inputs and reducing costs without sacrificing yield.

In addition to economic benefits, RhizoSorb^® delivers meaningful environmental advantages, reducing CO₂e emissions by 45.2%, phosphorus runoff by 78%, and leaching by 84% compared to conventional MAP fertilizer.

“With approximately 94.5 million acres of crop production that depend on phosphate, Canada is a key market,” said Craig Dick, VP Sales and Marketing. “We are proud to partner with MustGrow to deliver RhizoSorb^® to retailers and growers across Canada.”

“This partnership marks another major milestone in Phospholutions’ journey,” added Hunter Swisher, CEO of Phospholutions. “Partnering to bring more cost-effective fertilizer solutions to the Canadian market supports our broader global expansion efforts.”

“MustGrow and Phospholutions share a common mission to improve the global food system through sustainable production solutions,” said Colin Bletsky, COO of MustGrow. “Phosphorus is the second-most-used nutrient in global food production, making its efficient and responsible use a top priority for both our companies and the growers we serve.”

Benefits of Reduced-Rate Phosphate

RhizoSorb^® features a 38% lower salt index, promoting healthier soils and long-term productivity. Growers benefit from lower application rates, reduced input costs, and sustained yields. For retailers, it offers reduced storage and logistics costs along with stronger margins. Environmentally, RhizoSorb^® cuts CO₂ emissions by reducing carbon-intensive ingredients during manufacturing, reducing logistics across import, retail, and farm.

About Phospholutions Inc.

Phospholutions’ mission is to enhance global phosphorus use. It believes that sustainable production and responsible use of phosphorus is critical to support global food demands. RhizoSorb^® was developed to cut costs and reduce the environmental impact of fertilizer use by releasing nutrients in the soil more efficiently. Phospholutions’ patented fertilizer is incorporated into production to create higher efficiency products that maximize the use of phosphate resources. For further details, please visit www.phospholutions.com.

About MustGrow

MustGrow is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Forward-looking statements in this press release, including statements about the ability of RhizoSorb^® to reduce costs, environmental impacts, and strengthen retailer profit margins, are subject to a number of risks and uncertainties that may cause the actual results of MustGrow and its distributed products to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include the accuracy of the information provided by Phospholutions Inc. regarding RhizoSorb® as well as those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

¹All statements contained in this press release about product efficacy of RhizoSorb^®and conventional phosphorus fertilizer are based on information from Phospholutions about their field testing RhizoSorb^®in over 500 trials across 14 states for four years.